EPRX: Held by 1 Biotech Hedge Fund (2026) | BiotechEdge

Catalysts Convergence Squeeze SignalsNEW Cash Runway Insiders M&A Research

Home›Companies›EUPRAXIA PHARMACEUTICALS INC. (EPRX)

EUPRAXIA PHARMACEUTICALS INC.

EPRX

Held by 1 specialist biotech fund

High short interest · No specialist buying

1 fund opened new positions. Next phase2 readout (EP-104GI): Dec 2026.

Score Holdings Short Interest Catalysts Insiders Research

BiotechEdge

Catalysts Conferences Companies Convergence Fund Insiders Signals Squeeze Cash Runway Research Weekly Briefs 13F Changes Glossary PricingSign In Start 14-Day Free Trial

Data sourced from SEC EDGAR and ClinicalTrials.gov. Not investment advice.

Feedback

Signal Score

1.5/10

1 fund opened new positions●●

No recent insider activity●●

Phase2 readout expected Dec 2026●●

Held by 1 specialist fund●●

See how each signal contributes— fund overlap, insider activity, catalyst timing, short interest (free trial)

Conviction + Catalyst

1 specialist fund hold EPRX with a Phase 2 in 224 days for EP-104GI (Eosinophilic Esophagitis)

Redmile Group

Fund Holdings

Redmile GroupNew

Short Interest

High short interest

Short Shares

2.57M

Change

+1.0%

Days to Cover

18.9

Settlement

Apr 30, 2026

Short interest over 2 periods

Catalysts

Phase 2Q4 2026EP-104GIEosinophilic EsophagitisNCT05608681

Be first to know when this name moves

Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.

Position Details

Redmile GroupNEW POSITIONMay 15, 2026

Start free trialfor share counts, dollar values & AI analysis

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Insider Signals

No insider purchases or sales detected in the past 90 days.

Also Held by These Funds

VERV1 fund XERS1 fund SLNCF1 fund FDMT1 fund ETNB1 fund ABSI1 fund ACIU1 fund ADCT1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Related Research

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Verdad's Biotech White Paper, Part 2: Why Traditional Quant Factors Fail — and What Works Instead

6 min read

Fund Convergence: The Highest-Conviction Signal in Biotech Investing

5 min read

Track specialist biotech funds, insider signals, and AI analysis

Start 14-Day Free Trial

Get free weekly alerts on fund moves and catalysts:

Terms

Privacy

Disclaimer